Helixmith Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 66


  • Stock Symbol
  • 084990

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $3.40
  • (As of Tuesday Closing)

Helixmith General Information


Helixmith Co Ltd, formerly ViroMed Co Ltd is active in the healthcare sector in Korea. The company specializes in developing pharmaceutical products for the treatment of diseases related to peripheral artery, coronary artery, cardiovascular system and neuropathy, cancer and allergy. Its suite of products includes protein/deoxyribonucleic acid (DNA)-based biopharmaceuticals, botanical drugs and natural pharmaceuticals.

Contact Information

Formerly Known As
ViroMedica Pacific, Viromed
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Corporate Office
  • 21, Magokjungang 8-Ro 7-Gil
  • No. 599 Gwanak-Ro, Gwanak-Gu
  • Seoul, Gangseo-gu 07794
  • South Korea
+82 00-0000-0000

Helixmith Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Helixmith Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.40 $3.34 $2.43 - $6.87 $167M 49M 494K -$1.18

Helixmith Financials Summary

In Thousands,
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 186,997 186,997 334,615 626,401
Revenue 3,214 3,214 2,167 2,022
EBITDA (42,967) (42,967) (25,371) (48,517)
Net Income (49,018) (49,018) (33,695) (44,471)
Total Assets 176,366 176,366 201,172 237,392
Total Debt 15,696 15,696 16,288 27,291
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Helixmith Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Helixmith‘s full profile, request access.

Request a free trial

Helixmith Executive Team (6)

Name Title Board Seat Contact Info
Jeong Ji-wook Co-Chief Executive Officer & President
Sunyoung Kim Ph.D Co-Founder & Chief Executive Officer
Seungshin Yu Ph.D Chief Technology Officer & President
Bu-Hyeok Yoon President
Jong-Mook Kim Ph.D Co-Founder, Co-Chief Executive Officer & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Helixmith Board Members (1)

Name Representing Role Since
Jong-Mook Kim Ph.D Helixmith Co-Founder, Co-Chief Executive Officer & Board Member 000 0000
To view Helixmith’s complete board members history, request access »

Helixmith Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Helixmith Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Helixmith‘s full profile, request access.

Request a free trial

Helixmith Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vical (DNA Production Facility) 20-Aug-2018 000000000 Buildings and Property 00000000
Wacker Biotech US 01-Aug-2018 00000 0000 BPO/Outsource Services
Helixir (Drug Discovery) 10-Nov-2009 Merger/Acquisition Drug Discovery
To view Helixmith’s complete investments and acquisitions history, request access »

Helixmith ESG

Risk Overview

Risk Rating

Updated September, 15, 2023

30.34 | High Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,173






00 of 909






00 of 401




To view Helixmith’s complete esg history, request access »

Helixmith Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Wacker Biotech US 01-Aug-2018 00000 0000000 Completed
  • 2 buyers
To view Helixmith’s complete exits history, request access »

Helixmith FAQs

  • When was Helixmith founded?

    Helixmith was founded in 1996.

  • Who is the founder of Helixmith?

    Sunyoung Kim Ph.D and Jong-Mook Kim Ph.D are the founders of Helixmith.

  • Who is the CEO of Helixmith?

    Jeong Ji-wook and Sunyoung Kim Ph.D are the CEOs of Helixmith.

  • Where is Helixmith headquartered?

    Helixmith is headquartered in Seoul, South Korea.

  • What is the size of Helixmith?

    Helixmith has 66 total employees.

  • What industry is Helixmith in?

    Helixmith’s primary industry is Biotechnology.

  • Is Helixmith a private or public company?

    Helixmith is a Public company.

  • What is Helixmith’s stock symbol?

    The ticker symbol for Helixmith is 084990.

  • What is the current stock price of Helixmith?

    As of 23-Apr-2024 the stock price of Helixmith is $3.40.

  • What is the current market cap of Helixmith?

    The current market capitalization of Helixmith is $167M.

  • What is Helixmith’s current revenue?

    The trailing twelve month revenue for Helixmith is $3.21M.

  • What is Helixmith’s annual earnings per share (EPS)?

    Helixmith’s EPS for 12 months was -$1.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »